Teva UK and Closed Loop Medicine announce strategic partnership to advance the development of personalized medicines

Teva UK and Closed Loop Medicine announce strategic partnership to advance the development of personalized medicines

Under the agreement, Closed Loop Medicine - a leading TechBio company - and pharmaceutical company Teva UK will explore opportunities to leverage Closed Loop Medicine's proprietary software as a medical device technology platform (SaMD), aimed at advancing the development of personalized medicines and improving drug efficacy and outcomes in patients with specific chronic diseases by combining dose-optimized drug therapy with digital care.

said Dr. Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine: "As clinicians, we know that medication dosing is a major problem. In the most extreme cases, patients experience serious adverse events, such as when a dosage change is required to undergo surgery. The ability to predict personalized dosage levels could be a game-changer."

This strategic partnership leverages Closed Loop Medicine's proprietary SaMD and combines it with Teva's pharmaceutical products, creating the ability to prescribe digital companions alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and well-known medicines.

Recent clinical trial results for a hypertension product, CLM-HT01, have demonstrated the technology's ability to dose-optimize drug therapy and minimize side effects while achieving blood pressure control with exceptionally high medication adherence.1

Personalized medicine is a goal of the modern healthcare system, but existing medications are typically prescribed based on their average effect in a population and are rarely dose-optimized for the individual. This “one-size-fits-all” approach leads to increased side effects and side effects, medication nonadherence, and consequently poorer patient outcomes and higher healthcare costs for payers. For example, the annual cost of drug-related morbidity and mortality due to non-optimized medicines in the US was estimated at $528.4 billion in 20162, and the projected annual cost of adverse drug reactions alone to the NHS is £2.21 billion. 3

Kim Innes, Teva's general manager for the UK and Ireland, said:"We are delighted to be working with Closed Loop Medicine, who have proven to be strong innovators in the field of personalized medicine. We know that the patient experience can sometimes be sub-optimal, and as the largest medicines supplier to the NHS, the combination of medicine and digital could significantly improve patients' lives. We are very excited about the future of this partnership.”

Dr. Hakim Yadi OBE, CEO and co-founder of Closed Loop Medicine, commented:“It is a fantastic opportunity to work with the Teva team to explore ways in which our combined expertise can advance the delivery of personalized healthcare solutions globally.”He added:"Integrating real-world data enables dosage personalization that was not previously readily available to physicians. This commercial partnership is an example of the potential and scalability of our SaMD technology platform and demonstrates the value that can be created by integrating software with well-known and trusted brands to improve disease management and patient outcomes at the individual level."

1. Collier DJ, et al. Personalisierte blutdrucksenkende Behandlungsoptimierung mit Smartphone-fähiger ferngesteuerter Präzisionsdosierung von Amlodipin während der COVID-19-Pandemie (PERSONAL-CovidBP-Studie). 2024 https://www.ahajournals.org/doi/10.1161/JAHA.123.030749 [accessed February 2024]
2. Watanabe JH et al. Kosten für Morbidität und Mortalität im Zusammenhang mit verschreibungspflichtigen Arzneimitteln. Annalen der Pharmakotherapie. 2018;52(9):829-837
3. Osanlou R, et al. Unerwünschte Arzneimittelwirkungen, Multimorbidität und Polypharmazie: eine prospektive Analyse der ärztlichen Einweisungen eines Monats. BMJ offen. 2022;12(7):e055551

Sources: